Cell Line Characterization and Cell Line Development Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions
Description
Cell Line Characterization and Cell Line Development Market: Overview
As per Roots Analysis, the cell line characterization and cell line development market is USD is projected to grow from USD 2.71 billion in the current year and is expected to reach USD 8.38 billion by 2035, representing a CAGR of 12% during the forecast period.
Cell Line Characterization and Cell Line Development Market
The market sizing and opportunity analysis has been segmented across the following parameters:
Source of Cell Lines / Expression System
Over the years, the increasing potential of biopharmaceuticals (for addressing challenging indications, such as immunological, oncological, and rare diseases) and the emergence of innovative technologies for developing groundbreaking biological therapies have captured the attention of various industry and academic participants. At present, over 200 biologics have entered the market, with more than 10,000 candidates undergoing clinical assessment. Moreover, the creation and production of biologics require living biological systems or cell lines. Cell lines consist of a collection of cells originating from a single cell and are maintained in laboratories with suitable growth medium. Significantly, there has been an increase in the need for various types of cell lines (such as mammalian (human and non-human cell lines), microbial, insect, marine, and avian cell lines). At present, approximately 70% of all recombinant protein therapeutics are manufactured using Chinese Hamster Ovary cells (CHO cells).
The development and authentication of cell lines is a complex and costly process that demands expertise from multiple fields. Indeed, given their essential function in drug discovery and development, cell lines must undergo proper testing and validation; this additionally helps avoid misidentification of cell lines, identifies contaminants or harmful microorganisms, tracks genetic stability, and confirms the authenticity of experimental research. As a result, pharmaceutical developers are progressively depending on service providers possessing specialized tools and knowledge to tackle technical and operational issues (such as variations in gene expression and impurities in cell lines). Additionally, engaging with service providers allows drug developers / sponsors to utilize cutting-edge and superior technologies (offered by the service provider) and obtain enhanced operational adaptability. Due to the increasing demand for innovative biologics (such as cell therapies, gene therapies, monoclonal antibodies, recombinant proteins, and vaccines), continuous technological advancements, and a growing trend towards outsourcing, the sector for cell line development and characterization service providers is expected to expand in the near future.
Cell Line Characterization and Cell Line Development Market: Key Insights
The report delves into the current state of the global cell line characterization and cell line development market and identifies potential growth opportunities within industry. Some key findings from the report include:
Mammalian Cell Lines Currently Holds the Majority of the Market Share
In terms of source of cell lines, the global cell line characterization and cell line development market is segmented across mammalian, microbial, insect and other cell lines. The segment of mammalian cell lines currently holds the largest share (in terms of both development and characterization forecasts) and is anticipated to experience significant growth in the upcoming years.
Majority of the Market Share is Application of Cell Line
The global cell line characterization and cell line development market is segmented into bioproduction and research and development operations. Among these segments, it has been observed that majority share of the cell line development market is currently captured by cell lines developed for bioproduction. This can be attributed to the fact that the rising incidence of chronic diseases has led to the need for developing high-quality biologics, such as monoclonal antibodies and recombinant proteins.
Asia-Pacific is Likely to Grow at a Healthy CAGR During the Forecast Period
This segment highlights the distribution of cell line characterization and cell line development market across various geographies, such as North America, Europe, and Asia-Pacific and rest of the world regions. According to our projections, the cell line development market in North America is likely to capture majority (41%) of the overall market share, and this trend is unlikely to change in the future. In addition, in cell line characterization market, Asia-Pacific and rest of the world is expected to grow at a relatively healthy CAGR (12.1%), during the forecast period, till 2035.
Primary Research Overview
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
As per Roots Analysis, the cell line characterization and cell line development market is USD is projected to grow from USD 2.71 billion in the current year and is expected to reach USD 8.38 billion by 2035, representing a CAGR of 12% during the forecast period.
Cell Line Characterization and Cell Line Development Market
The market sizing and opportunity analysis has been segmented across the following parameters:
Source of Cell Lines / Expression System
- Mammalian
- Microbial
- Insect
- Others
- Research and Development
- Drug Development
- Very Large and Large
- Mid-sized
- Small
- North America
- Europe
- Asia-Pacific and Rest of the World
Over the years, the increasing potential of biopharmaceuticals (for addressing challenging indications, such as immunological, oncological, and rare diseases) and the emergence of innovative technologies for developing groundbreaking biological therapies have captured the attention of various industry and academic participants. At present, over 200 biologics have entered the market, with more than 10,000 candidates undergoing clinical assessment. Moreover, the creation and production of biologics require living biological systems or cell lines. Cell lines consist of a collection of cells originating from a single cell and are maintained in laboratories with suitable growth medium. Significantly, there has been an increase in the need for various types of cell lines (such as mammalian (human and non-human cell lines), microbial, insect, marine, and avian cell lines). At present, approximately 70% of all recombinant protein therapeutics are manufactured using Chinese Hamster Ovary cells (CHO cells).
The development and authentication of cell lines is a complex and costly process that demands expertise from multiple fields. Indeed, given their essential function in drug discovery and development, cell lines must undergo proper testing and validation; this additionally helps avoid misidentification of cell lines, identifies contaminants or harmful microorganisms, tracks genetic stability, and confirms the authenticity of experimental research. As a result, pharmaceutical developers are progressively depending on service providers possessing specialized tools and knowledge to tackle technical and operational issues (such as variations in gene expression and impurities in cell lines). Additionally, engaging with service providers allows drug developers / sponsors to utilize cutting-edge and superior technologies (offered by the service provider) and obtain enhanced operational adaptability. Due to the increasing demand for innovative biologics (such as cell therapies, gene therapies, monoclonal antibodies, recombinant proteins, and vaccines), continuous technological advancements, and a growing trend towards outsourcing, the sector for cell line development and characterization service providers is expected to expand in the near future.
Cell Line Characterization and Cell Line Development Market: Key Insights
The report delves into the current state of the global cell line characterization and cell line development market and identifies potential growth opportunities within industry. Some key findings from the report include:
- Presently, over 200 players (established as well as start ups) claim to have the necessary capabilities to offer cell line development services; majority of these firms are based in North America.
- Stakeholders have the capability to develop cell lines obtained from different sources that support cell-based research and development operations and facilitate production of biotherapeutics.
- In pursuit of building a competitive edge, players are actively upgrading their existing capabilities to enhance their respective service offerings and comply with the evolving industry benchmarks.
- Over 140 service providers (industry and non-industry) claim to offer cell line characterization services; a sizeable proportion of these players offer genotyping services for accessing the identity and stability of cell lines.
- Majority of the cell line characterization service providers are small and mid-sized firms, established post-2000; notably, around 10% of the players offer all types of characterization services.
- In order to cater to the rising demand of novel biologics (developed using cell lines), service providers are upgrading their technical expertise and adding new competencies to augment their service portfolios.
- Both well-established players and new entrants have forged strategic partnerships; licensing agreements have been the most common.
- To keep pace with the growing demand for cell lines, companies have made significant investments to expand their facilities and capacities; this trend is most pronounced in the US and China.
- In the long-term, cell line development services market is expected to witness growth of 12%; the opportunity is likely to be well distributed across different sources of cell lines, application areas and geographies.
Mammalian Cell Lines Currently Holds the Majority of the Market Share
In terms of source of cell lines, the global cell line characterization and cell line development market is segmented across mammalian, microbial, insect and other cell lines. The segment of mammalian cell lines currently holds the largest share (in terms of both development and characterization forecasts) and is anticipated to experience significant growth in the upcoming years.
Majority of the Market Share is Application of Cell Line
The global cell line characterization and cell line development market is segmented into bioproduction and research and development operations. Among these segments, it has been observed that majority share of the cell line development market is currently captured by cell lines developed for bioproduction. This can be attributed to the fact that the rising incidence of chronic diseases has led to the need for developing high-quality biologics, such as monoclonal antibodies and recombinant proteins.
Asia-Pacific is Likely to Grow at a Healthy CAGR During the Forecast Period
This segment highlights the distribution of cell line characterization and cell line development market across various geographies, such as North America, Europe, and Asia-Pacific and rest of the world regions. According to our projections, the cell line development market in North America is likely to capture majority (41%) of the overall market share, and this trend is unlikely to change in the future. In addition, in cell line characterization market, Asia-Pacific and rest of the world is expected to grow at a relatively healthy CAGR (12.1%), during the forecast period, till 2035.
Primary Research Overview
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Chief Executive Officer, Small Company, UK
- Principal Scientist and Head, R&D, Mid-size Company, India
- Director, Business Development and Marketing, Mid-size Company, France
- Founder and Managing Director, Small Company, Germany
- Chief Executive Officer, Mid-sized Company, China
- Former Chief Scientific Officer, Large Company, Poland
- Director of Business Development and Marketing, Mid-Sized Company, France
- Director of Client Relations, Mid-Sized Company, US
- President, Small Company, US
- Former Vice President Bioprocessing, Very Large Company, US
- Former Global Business Development Manager, Large Company, Poland
- ATUM
- ATZ Labs (a subsidiary of Life Technologies)
- Avance Biosciences
- BioReliance (acquired by Sigma-Aldrich)
- Biovian
- Celonic Group
- Charles River Laboratories
- ChemPartner
- Cleancells
- Creative Biogene
- Curia
- Eurofins BioPharma Product Testing
- FUJIFILM Diosynth Biotechnologies
- Hylabs
- KBI Biopharma
- Kemp Proteins
- KMD Bioscience
- Livogen Pharmed
- Lonza
- Molecular Diagnostic Services
- Mycenax Biotech
- ProBioGen
- Samsung BioLogics
- Sartorius
- SGS Life Sciences
- Syngene International
- Texcell
- TFBS Bioscience
- Thermo Fisher Scientific
- WuXi Advanced Therapies
- WuXi Biologics
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell line characterization and cell line development market, focusing on key market segments, including [A] source of cell line / expression system, [B] application of cell line, [C] company size, and [D] key geographical regions.
- Market Landscape: A detailed analysis of the overall market landscape of cell line development service providers based on several relevant parameters, such as [A] Â year of establishment, [A] company size, [B] location of headquarters, [C] source of cell lines / expression systems offered, [D] gene delivery method used, [E] type of transfection, [F] availability of serum free / animal component free culturing capability, [G] type of cells offered, [H] application of cell lines, [I] additional cell line related services offered, [J] type of cell banking and [K] availability of integrated cell line characterization.
- Company Competitiveness Analysis: A comprehensive competitive analysis of  cell line development service providers, examining factors, such as [A] supplier strength and [B] service strength.
- Company Profiles: In-depth profiles of prominent players offering cell line development services, headquartered in North America, Europe and Asia-Pacific focusing on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
- Partnerships and Collaborations Analysis: A detailed analysis of the partnerships inked between stakeholders engaged in this industry, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of cells involved, [D] therapeutic area, [E] type of partner and [F] most active players (in terms of the number of partnerships signed).
- Recent Expansions: A detailed analysis of the recent expansions undertaken by various cell line development and cell line characterization service providers, based on various relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] location of headquarters, [D] location of expanded facility, [E] area of expanded facility, [F] purpose of expansion, [G] most active players (in terms of number of recent expansions) and [H] geographical distribution.
- Cell Line Repositories: Detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio.Â
- Regulatory Recommendations and Guidelines: An elaborate discussion on the requirements established by various regulatory authorities across different regions, related to characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes / organizations involved in this domain.
- Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of cell line development and characterization market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- Complimentary PPT Insights Packs
Table of Contents
455 Pages
- 1. Preface
- 1.1. Introduction
- 1.2. Project Objectives
- 1.3. Scope Of The Report
- 1.4. Inclusions And Exclusions
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. Covid Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
- 3. Economic And Other Project Specific Considerations
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current And Forecasted Estimates
- 3.2.2. Currency Coverage
- 3.2.2.1. Overview Of Major Currencies Affecting The Market
- 3.2.2.2. Impact Of Currency Fluctuations On The Industry
- 3.2.3. Foreign Exchange Impact
- 3.2.3.1. Evaluation Of Foreign Exchange Rates And Their Impact On Market
- 3.2.3.2. Strategies For Mitigating Foreign Exchange Risk
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis Of Past Recessions And Lessons Learnt
- 3.2.4.2. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 3.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 4. Executive Summary
- 5. Introduction
- 5.1. Chapter Overview
- 5.2. Overview Of Cell Culture
- 5.2.1. Classification Of Cell Cultures
- 5.2.1.1. Classification Based On Origin
- 5.2.1.1.1. Primary Cell Cultures
- 5.2.1.1.2. Secondary Cell Cultures
- 5.2.1.2. Classification Based On Growth Properties
- 5.2.1.2.1. Adherent Cell Cultures
- 5.2.1.2.2. Suspension Cell Cultures
- 5.2.2. Classification Of Cell Lines
- 5.2.2.1. Classification Based On Lifespan Of Cell Line
- 5.2.2.1.1. Finite Cell Lines
- 5.2.2.1.2. Continuous Cell Lines
- 5.2.2.2. Classification Based On Type Of Cell Line
- 5.2.2.2.1. Recombinant Cell Lines
- 5.2.2.2.2. Hybridoma Cell Lines
- 5.2.2.3. Classification Based On Source Of Cell Line
- 5.2.2.3.1. Mammalian Cell Lines
- 5.2.2.3.2. Non-mammalian Cell Lines
- 5.3. Overview Of Cell Line Characterization
- 5.3.1. Cell Line Characterization Methods
- 5.3.1.1. Identity / Stability Testing
- 5.3.1.1.1. Karyotype Analysis
- 5.3.1.1.2. Cytochrome C Oxidase I Barcoding Assay
- 5.3.1.1.3. Cell Morphology Analysis
- 5.3.1.1.4. Dna Analysis
- 5.3.1.2. Sterility / Biosafety Testing
- 5.3.1.2.1. Mycoplasma Contamination Testing
- 5.3.1.2.2. Viral Contamination Testing
- 5.4. Applications Of Cell Lines
- 5.5. Key Concerns Associated With Cell Lines
- 5.6. Need For Outsourcing Cell Line Related Operations
- 5.7. Concluding Remarks
- 6. Cell Line Development Service Providers: Market Landscape
- 6.1. Chapter Overview
- 6.2. Cell Line Development Service Providers: Overall Market Landscape
- 6.2.1. Analysis By Year Of Establishment
- 6.2.2. Analysis By Company Size
- 6.2.3. Analysis By Location Of Headquarters
- 6.2.4. Analysis By Company Size And Location Of Headquarters
- 6.2.5. Analysis By Source Of Cell Line / Expression System Offered
- 6.2.6. Analysis By Gene Delivery Method Used
- 6.2.7. Analysis By Type Of Transfection
- 6.2.8. Analysis By Availability Of Serum-free / Animal Component Free Culturing Capability
- 6.2.9. Analysis By Type Of Cells Offered
- 6.2.10. Analysis By Application Of Cell Lines
- 6.2.11. Analysis By Additional Cell Line Related Services Offered
- 6.2.12. Analysis By Type Of Cell Banking
- 6.2.13. Analysis By Availability Of Integrated Cell Line Characterization Service
- 7. Cell Line Development Service Providers: Company Competitiveness Analysis
- 7.1. Chapter Overview
- 7.2. Assumptions / Key Parameters
- 7.3. Methodology
- 7.4. Cell Line Development Service Providers: Company Competitiveness Analysis
- 7.4.1. Cell Line Development Service Providers In North America
- 7.4.2. Cell Line Development Service Providers In Europe
- 7.4.3. Cell Line Development Service Providers In Asia-pacific
- 8. Company Profiles: Cell Line Development Service Providers
- 8.1. Chapter Overview
- 8.2. Detailed Company Profiles Of Leading Service Providers
- 8.2.1. Atum
- 8.2.1.1. Company Overview
- 8.2.1.2. Cell Line Development Service Portfolio
- 8.2.1.3. Recent Developments And Future Outlook
- 8.2.2. Curia
- 8.2.2.1. Company Overview
- 8.2.2.2. Cell Line Development Service Portfolio
- 8.2.2.3. Recent Developments And Future Outlook
- 8.2.3. Fujifilm Diosynth Biotechnologies
- 8.2.3.1. Company Overview
- 8.2.3.2. Service Portfolio For Cell Line Development
- 8.2.3.3. Recent Developments And Future Outlook
- 8.2.4. Lonza
- 8.2.4.1. Company Overview
- 8.2.4.2. Cell Line Development Service Portfolio
- 8.2.4.3. Recent Developments And Future Outlook
- 8.2.5. Syngene International
- 8.2.5.1. Company Overview
- 8.2.5.2. Cell Line Development Service Portfolio
- 8.2.5.3. Recent Developments And Future Outlook
- 8.2.6. Wuxi Biologics
- 8.2.6.1. Company Overview
- 8.2.6.2. Cell Line Development Service Portfolio
- 8.2.6.3. Recent Developments And Future Outlook
- 8.3. Short Profiles Of Other Prominent Service Providers
- 8.3.1. Biovian
- 8.3.1.1. Company Overview
- 8.3.1.2. Cell Line Development Service Portfolio
- 8.3.2. Celonic
- 8.3.2.1. Company Overview
- 8.3.2.2. Cell Line Development Service Portfolio
- 8.3.3. Chempartner
- 8.3.3.1. Company Overview
- 8.3.3.2. Cell Line Development Service Portfolio
- 8.3.4. Creative Biogene
- 8.3.4.1. Company Overview
- 8.3.4.2. Cell Line Development Service Portfolio
- 8.3.5. Kbi Biopharma
- 8.3.5.1. Company Overview
- 8.3.5.2. Cell Line Development Service Portfolio
- 8.3.6. Kemp Proteins
- 8.3.6.1. Company Overview
- 8.3.6.2. Cell Line Development Service Portfolio
- 8.3.7. Kmd Bioscience
- 8.3.7.1. Company Overview
- 8.3.7.2. Cell Line Development Service Portfolio
- 8.3.8. Mycenax Biotech
- 8.3.8.1. Company Overview
- 8.3.8.2. Cell Line Development Service Portfolio
- 8.3.9. Probiogen
- 8.3.9.1. Company Overview
- 8.3.9.2. Cell Line Development Service Portfolio
- 8.3.10. Thermo Fisher Scientific
- 8.3.10.1. Company Overview
- 8.3.10.2. Cell Line Development Service Portfolio
- 9. Cell Line Characterization Service Providers: Market Landscape
- 9.1. Chapter Overview
- 9.2. Cell Line Characterization Service Providers: Overall Market Landscape
- 9.2.1. Cell Line Characterization Service Providers Service Providers (Industry Players)
- 9.2.1.1. Analysis By Year Of Establishment
- 9.2.1.2. Analysis By Company Size
- 9.2.1.3. Analysis By Location Of Headquarters
- 9.2.1.4. Analysis By Location Of Headquarters And Company Size
- 9.2.1.5. Analysis By Cell Line Characterized
- 9.2.1.6. Analysis By Type Of Cell Line Characterization Service Offered
- 9.2.1.6.1. Analysis By Type Of Cell Line Identity / Stability Testing Service Offered
- 9.2.1.6.2. Analysis By Type Of Cell Line Sterility / Biosafety Testing Service Offered
- 9.2.2. Cell Line Characterization Service Providers (Non-industry Players)
- 9.2.2.1. Analysis By Location Of Organization
- 9.2.2.2. Analysis By Types Of Cell Line Characterized
- 9.2.2.3. Analysis By Type Of Cell Line Characterization Service Offered
- 9.2.2.4. Analysis By Genotyping Kit Used
- 9.2.2.5. Analysis By Number Of Loci Amplified
- 10. Cell Line Characterization Service Providers: Company Competitiveness Analysis
- 10.1. Chapter Overview
- 10.2. Assumptions / Key Parameters
- 10.3. Methodology
- 10.4. Cell Line Characterization Service Providers: Company Competitiveness Analysis
- 10.4.1. Cell Line Characterization Service Providers In North America
- 10.4.2. Cell Line Characterization Service Providers In Europe
- 10.4.3. Cell Line Characterization Service Providers In Asia-pacific
- 11. Company Profiles: Cell Line Characterization Service Providers
- 11.1. Chapter Overview
- 11.2. Detailed Company Profiles Of Leading Service Provider
- 11.2.1 Charles River Laboratories
- 11.2.1.1. Company Overview
- 11.2.1.2. Cell Line Characterization Service Portfolio
- 11.2.1.3. Recent Developments And Future Outlook
- 11.2.2. Eurofins Biopharma Product Testing
- 11.2.2.1. Company Overview
- 11.2.2.2. Cell Line Characterization Service Portfolio
- 11.2.2.3. Recent Developments And Future Outlook
- 11.2.3. Livogen Pharmed
- 11.2.3.1. Company Overview
- 11.2.3.2. Cell Line Characterization Service Portfolio
- 11.2.3.3. Recent Developments And Future Outlook
- 11.2.4. Molecular Diagnostic Services
- 11.2.4.1. Company Overview
- 11.2.4.2. Cell Line Characterization Service Portfolio
- 11.2.4.3. Recent Developments And Future Outlook
- 11.2.5. Sartorius
- 11.2.5.1. Company Overview
- 11.2.5.2. Cell Line Characterization Service Portfolio
- 11.2.5.3. Recent Developments And Future Outlook
- 11.2.6. Tfbs Bioscience
- 11.2.6.1. Company Overview
- 11.2.6.2. Cell Line Characterization Service Portfolio
- 11.2.6.3. Recent Developments And Future Outlook
- 11.3. Short Profiles Of Other Prominent Service Providers
- 11.3.1. Atz Labs (Subsidiary Of Life Technologies)
- 11.3.1.1. Company Overview
- 11.3.1.2. Cell Line Characterization Service Portfolio
- 11.3.2. Avance Biosciences
- 11.3.2.1. Company Overview
- 11.3.2.2. Cell Line Characterization Service Portfolio
- 11.3.3. Bioreliance
- 11.3.3.1. Company Overview
- 11.3.3.2. Cell Line Characterization Service Portfolio
- 11.3.4. Clean Cells
- 11.3.4.1. Company Overview
- 11.3.4.2. Cell Line Characterization Service Portfolio
- 11.3.5. Hylabs
- 11.3.5.1. Company Overview
- 11.3.5.2. Cell Line Characterization Service Portfolio
- 11.3.6. Samsung Biologics
- 11.3.6.1. Company Overview
- 11.3.6.2. Cell Line Characterization Service Portfolio
- 11.3.7. Sgs Life Sciences
- 11.3.7.1. Company Overview
- 11.3.7.2. Cell Line Characterization Service Portfolio
- 11.3.8. Texcell
- 11.3.8.1. Company Overview
- 11.3.8.2. Cell Line Characterization Service Portfolio
- 11.3.9. Wuxi Advanced Therapies
- 11.3.9.1. Company Overview
- 11.3.9.2. Cell Line Characterization Service Portfolio
- 12. Partnerships And Collaborations
- 12.1. Chapter Overview
- 12.2. Partnership Models
- 12.3. Cell Line Development And Characterization: Partnerships And Collaborations
- 12.3.1. Analysis By Year Of Partnership
- 12.3.2. Analysis By Type Of Partnership
- 12.3.3. Analysis By Year And Type Of Partnership
- 12.3.4. Analysis By Type Of Partner
- 12.3.5. Most Active Players: Analysis By Number Of Partnerships
- 12.3.6. Analysis By Geography
- 12.3.6.1. Intracontinental And Intercontinental Deals
- 12.3.6.2. International And Local Deals
- 13. Recent Expansions
- 13.1. Chapter Overview
- 13.2. Cell Line Development And Characterization: List Of Recent Expansions
- 13.2.1. Analysis By Year Of Expansion
- 13.2.2. Analysis By Type Of Expansion
- 13.2.3. Analysis By Year And Type Of Expansion
- 13.2.4. Analysis By Location Of Headquarters And Company Size
- 13.2.5. Analysis By Location Of Expanded Facility
- 13.2.6. Analysis By Type Of Expansion And Location Of Expanded Facility
- 13.2.7. Analysis By Area Of Expanded Facility (Sq Ft)
- 13.2.8. Analysis By Purpose Of Expansion
- 13.2.9. Analysis By Geography
- 13.2.10. Most Active Players: Analysis By Number Of Recent Expansions
- 14. Cell Line Repositories
- 14.1. Chapter Overview
- 14.2. American Type Culture Collection (Atcc)
- 14.2.1. Overview
- 14.2.2. Service Portfolio
- 14.3. Coriell Institute For Medical Research
- 14.3.1. Overview
- 14.3.2. Service Portfolio
- 14.4. European Collection Of Authenticated Cell Cultures (Ecacc)
- 14.4.1. Overview
- 14.4.2. Service Portfolio
- 14.5. Leibniz Institute Dsmz - German Collection Of Microorganisms And Cell Cultures
- 14.5.1. Overview
- 14.5.2. Service Portfolio
- 14.6. National Centre For Cell Science (Nccs)
- 14.6.1. Overview
- 14.6.2. Service Portfolio
- 15. Regulatory Recommendations And Guidelines
- 15.1. Chapter Overview
- 15.2. Cell Line Authentication: Prominent Regulatory Authorities
- 15.2.1. Role Of American Type Culture Collection (Atcc)
- 15.2.2. Role Of International Cell Line Authentication Committee (Iclac)
- 15.2.3. Role Of Global Biological Standards Institute (Gbsi)
- 15.3. Guidelines Issued By International Regulatory Agencies
- 15.3.1. World Health Organization
- 15.3.2. The International Council For Harmonization Of Technical Requirements For Pharmaceuticals For Human Use (Ich)
- 15.4. Regulatory Guidelines For Cell Line Characterization In The Us
- 15.4.1. Food And Drug Administration
- 15.4.1.1. Fda Points To Consider
- 15.4.1.2. Us Pharmacopeial Convention
- 15.4.1.3. Us Code For Federal Regulations
- 15.5. Regulatory Guidelines For Cell Line Characterization In Europe
- 15.5.1. European Medicines Agency
- 15.6. Regulatory Guidelines For Cell Line Characterization In Japan
- 15.6.1. Ministry Of Health, Labor And Welfare
- 15.7. Concluding Remarks
- 16. Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges
- 16.1. Chapter Overview
- 16.2. Market Drivers
- 16.3. Market Restraints
- 16.4. Market Opportunities
- 16.5. Market Challenges
- 16.6. Conclusion
- 17. Global Cell Line Development Services Market
- 17.1. Chapter Overview
- 17.2. Assumptions And Methodology
- 17.3. Global Cell Line Development Services Market, Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 17.3.1. Scenario Analysis
- 17.3.1.1. Conservative Scenario
- 17.3.1.2. Optimistic Scenario
- 17.4. Key Market Segmentations
- 18. Cell Line Development Services Market, By Source Of Cell Lines
- 18.1. Chapter Overview
- 18.2. Key Assumptions And Methodology
- 18.3. Cell Line Development Services Market: Distribution By Source Of Cell Lines
- 18.3.1. Cell Line Development Services Market For Mammalian Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 18.3.2. Cell Line Development Services Market For Microbial Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 18.3.3. Cell Line Development Services Market For Insect Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 18.3.4. Cell Line Development Services Market For Other Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 18.4. Data Triangulation And Validation
- 19. Cell Line Development Services Market, By Application Of Cell Lines
- 19.1. Chapter Overview
- 19.2. Key Assumptions And Methodology
- 19.3. Cell Line Development Services Market: Distribution By Application Of Cell Lines
- 19.3.1. Cell Line Development Services Market For Biomanufacturing: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 19.3.2. Cell Line Development Services Market For Research And Development Operations: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 19.4. Data Triangulation And Validation
- 20. Cell Line Development Services Market, By Company Size
- 20.1. Chapter Overview
- 20.2. Key Assumptions And Methodology
- 20.3. Cell Line Development Services Market: Distribution By Company Size
- 20.3.1. Cell Line Development Services Market For Large Companies: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 20.3.2. Cell Line Development Services Market For Mid-sized Companies: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 20.3.3. Cell Line Development Services Market For Small Companies: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 20.4. Data Triangulation And Validation
- 21. Cell Line Development Services Market, By Key Geographical Regions
- 21.1. Chapter Overview
- 21.2. Key Assumptions And Methodology
- 21.3. Cell Line Development Services Market: Distribution By Company Size
- 21.3.1. Cell Line Development Services Market For North America: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 21.3.2. Cell Line Development Services Market For Europe: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 21.3.3. Cell Line Development Services Market For Asia-pacific And Rest Of The World: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 21.4. Data Triangulation And Validation
- 22. Global Cell Line Characterization Services Market
- 22.1. Chapter Overview
- 22.2. Assumptions And Methodology
- 22.3. Global Cell Line Characterization Services Market, Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 22.3.1. Scenario Analysis
- 22.3.1.1. Conservative Scenario
- 22.3.1.2. Optimistic Scenario
- 22.4. Key Market Segmentations
- 23. Cell Line Characterization Services Market, By Source Of Cell Lines
- 23.1. Chapter Overview
- 23.2. Key Assumptions And Methodology
- 23.3. Cell Line Characterization Services Market: Distribution By Source Of Cell Lines
- 23.3.1. Cell Line Characterization Services Market For Mammalian Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 23.3.2. Cell Line Characterization Services Market For Microbial Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 23.3.3. Cell Line Characterization Services Market For Insect Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 23.3.4. Cell Line Characterization Services Market For Other Cell Lines: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 23.4. Data Triangulation And Validation
- 24. Cell Line Characterization Services Market, By Application Of Cell Lines
- 24.1. Chapter Overview
- 24.2. Key Assumptions And Methodology
- 24.3. Cell Line Characterization Services Market: Distribution By Application Of Cell Lines
- 24.3.1. Cell Line Characterization Services Market For Biomanufacturing: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 24.3.2. Cell Line Characterization Services Market For Research And Development Operations: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 24.4. Data Triangulation And Validation
- 25. Cell Line Characterization Services Market, By Company Size
- 25.1. Chapter Overview
- 25.2. Key Assumptions And Methodology
- 25.3. Cell Line Characterization Services Market: Distribution By Company Size
- 25.3.1. Cell Line Characterization Services Market For Large Companies: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 25.3.2. Cell Line Characterization Services Market For Mid-sized Companies: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 25.3.3. Cell Line Characterization Services Market For Small Companies: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 25.4. Data Triangulation And Validation
- 26. Cell Line Characterization Services Market, By Key Geographical Regions
- 26.1. Chapter Overview
- 26.2. Key Assumptions And Methodology
- 26.3. Cell Line Characterization Services Market: Distribution By Company Size
- 26.3.1. Cell Line Characterization Services Market For North America: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 26.3.2. Cell Line Characterization Services Market For Europe: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 26.3.3. Cell Line Characterization Services Market For Asia-pacific And Rest Of The World: Historical Trends (Since 2019) And Forecasted Estimates (Till 2035)
- 26.4. Data Triangulation And Validation
- 27. Concluding Remarks
- 28. Executive Insights
- 28.1. Chapter Overview
- 28.2. Company A
- 28.2.1. Company Snapshot
- 28.2.2. Interview Transcript: Chief Executive Officer
- 28.3. Company B
- 28.3.1. Company Snapshot
- 28.3.2. Interview Transcript: Principal Scientist And Head, R&D
- 28.4. Company C
- 28.4.1. Company Snapshot
- 28.4.2. Interview Transcript: Director, Business Development And Marketing
- 28.5. Company D
- 28.5.1. Company Snapshot
- 28.5.2. Interview Transcript: Founder And President
- 28.6. Company E
- 28.6.1. Company Snapshot
- 28.6.2. Interview Transcript: President
- 28.7. Company F
- 28.7.1. Company Snapshot
- 28.7.2. Interview Transcript: Chief Scientific Officer
- 28.8. Company G
- 28.8.1. Company Snapshot
- 28.8.2. Interview Transcript: Former Vice President Bioprocessing
- 28.9. Company H
- 28.9.1. Company Snapshot
- 28.9.2. Interview Transcript: Michael Pointek, Founder And Managing Director
- 28.10. Company I
- 28.10.1. Company Snapshot
- 28.10.2. Interview Transcript: Client Relations Manager
- 28.11. Company J
- 28.11.1. Company Snapshot
- 28.11.2. Interview Transcript: Former Business Development Manager
- 29. Appendix 1: Tabulated Data
- 30. Appendix 2: List Of Companies And Organizations
- 31. Appendix 3: Details Of Partnerships And Collaborations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.